Collectively, these composite results revealed that H2S donors alleviate lupus kidney injury by reducing the expression of the renal T-cell-related pro-inflammatory TF p65, which is a potential new therapeutic drug option in LN. This evidence concerns the gene TF and lobular neoplasia.